Dödligt virus från Kina orsakar panik (SARS-CoV-2, COVID-19)

Findings:
The primary analysis included 8811 SARS-CoV-2 positive participants (median symptom duration 5 days), randomised to ivermectin (n = 2157), usual care (n = 3256), and other treatments (n = 3398) from June 23, 2021 to July 1, 2022. Time to self-reported recovery was shorter in the ivermectin group compared with usual care (hazard ratio 1·15 [95% Bayesian credible interval, 1·07 to 1·23], median decrease 2.06 days [1·00 to 3·06]), probability of meaningful effect (pre-specified hazard ratio ≥1.2) 0·192). COVID-19-related hospitalisations/deaths (odds ratio 1·02 [0·63 to 1·62]; estimated percentage difference 0% [-1% to 0·6%]), serious adverse events (three and five respectively), and the proportion feeling fully recovered were similar in both groups at 6 months (74·3% and 71·2% respectively (RR = 1·05, [1·02 to 1·08]) and also at 3 and 12 months.

Interpretation:
Ivermectin for COVID-19 is unlikely to provide clinically meaningful improvement in recovery, hospital admissions, or longer-term outcomes. Further trials of ivermectin for SARS-Cov-2 infection in vaccinated community populations appear unwarranted.

Findings: The primary analysis included 8811 SARS-CoV-2 positive participants (median symptom duration 5 days), randomised to ivermectin (n = 2157), usual care (n = 3256), and other treatments (n = 3398) from June 23, 2021 to July 1, 2022. Time to self-reported recovery was shorter in the ivermectin group compared with usual care (hazard ratio 1·15 [95% Bayesian credible interval, 1·07 to 1·23], median decrease 2.06 days [1·00 to 3·06]), probability of meaningful effect (pre-specified hazard ratio ≥1.2) 0·192). COVID-19-related hospitalisations/deaths (odds ratio 1·02 [0·63 to 1·62]; estimated percentage difference 0% [-1% to 0·6%]), serious adverse events (three and five respectively), and the proportion feeling fully recovered were similar in both groups at 6 months (74·3% and 71·2% respectively (RR = 1·05, [1·02 to 1·08]) and also at 3 and 12 months.

Interpretation: Ivermectin for COVID-19 is unlikely to provide clinically meaningful improvement in recovery, hospital admissions, or longer-term outcomes. Further trials of ivermectin for SARS-Cov-2 infection in vaccinated community populations appear unwarranted.

Findings In this double-blind, randomized, placebo-controlled platform trial including 1432 US adults with COVID-19 during February 2022 to July 2022, the median time to sustained recovery was 11 days in the ivermectin group and 12 days in the placebo group. In this largely vaccinated (83%) population, the posterior probability that ivermectin reduced symptom duration by more than 1 day was less than 0.1%.

Meaning These findings do not support the use of ivermectin among outpatients with COVID-19.

New Delhi: The number of people who died in 24 Uttar Pradesh (UP) districts over nine months to 31 March 2021 was, cumulatively, 43 times higher than the total official Covid-19 death toll reported from these districts over this period, according to mortality data for India’s most-populous state.

The 24 districts—of 75 in UP—we chose reported the highest number of Covid-19 cases over the months of June, July, August, and October 2020 when the first wave struck, as per various media reports (here, here, & here) and government data tracked by Covid19india.org.

The excess deaths in these districts were between 10 to 335 times higher than the reported Covid-19 death toll between 1 July 2020 and 31 March 2021. The Bharatiya Janata Party has said UP’s chief minister Ajay Singh Bisht, popularly known as Yogi Adityanath “effectively managed” his state’s Covid-19 situation.

All the excess deaths cannot be attributed to Covid-19, and a diversion of health resources could cause other deaths to rise. But the vast divergence in average general deaths and excess deaths over a part of the pandemic calls into question UP’s official Covid-19 death toll of 4,537 by the end of March 2021.

Documents this reporter obtained for Article 14 under the Right to Information Act, 2005, revealed that during the no-pandemic period between 1 July 2019 and 31 March 2020 these 24 districts registered around 178,000 deaths. Over the same period in 2020-2021, deaths increased by 110% to 375,000, an excess of 197,000.
...
In the eastern UP district of Ghazipur, for instance, near Prime Minister Narendra Modi’s Parliamentary constituency of Varanasi and where bodies were found floating on the Ganga, around 19,700 people died between 1 July 2020 and 31 March 2021, compared to 1,600 over the same time period in 2019-20, an increase of 1,136%.